ME03454B - Terapeutski agensi za neurodegenerativne bolesti - Google Patents
Terapeutski agensi za neurodegenerativne bolestiInfo
- Publication number
- ME03454B ME03454B MEP-2019-169A MEP2019169A ME03454B ME 03454 B ME03454 B ME 03454B ME P2019169 A MEP2019169 A ME P2019169A ME 03454 B ME03454 B ME 03454B
- Authority
- ME
- Montenegro
- Prior art keywords
- therapeutic agents
- neurodegenerative diseases
- neurodegenerative
- diseases
- therapeutic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| EP17767934.7A EP3416631B1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
| PCT/IB2017/054929 WO2018029658A1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03454B true ME03454B (me) | 2020-01-20 |
Family
ID=59859424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-169A ME03454B (me) | 2016-08-11 | 2017-08-11 | Terapeutski agensi za neurodegenerativne bolesti |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20200179320A1 (me) |
| EP (2) | EP3583940A1 (me) |
| JP (3) | JP6957602B2 (me) |
| KR (2) | KR102413756B1 (me) |
| CN (3) | CN116492328A (me) |
| AU (2) | AU2017308865B2 (me) |
| BR (1) | BR112019002730A2 (me) |
| CA (1) | CA3033564A1 (me) |
| CY (1) | CY1121930T1 (me) |
| DK (1) | DK3416631T3 (me) |
| ES (1) | ES2733677T3 (me) |
| HR (1) | HRP20191055T1 (me) |
| HU (1) | HUE045043T2 (me) |
| IL (3) | IL310801A (me) |
| LT (1) | LT3416631T (me) |
| MA (2) | MA47521A (me) |
| MD (1) | MD3416631T2 (me) |
| ME (1) | ME03454B (me) |
| MX (2) | MX2019001575A (me) |
| PL (1) | PL3416631T3 (me) |
| PT (1) | PT3416631T (me) |
| RS (1) | RS59048B1 (me) |
| RU (2) | RU2021128045A (me) |
| SG (1) | SG11201901063SA (me) |
| SI (1) | SI3416631T1 (me) |
| TN (1) | TN2019000033A1 (me) |
| WO (1) | WO2018029658A1 (me) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3482754B1 (en) * | 2016-08-11 | 2020-12-23 | IntraBio Ltd | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| AU2018351709B2 (en) * | 2017-10-18 | 2024-01-04 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| WO2019159110A1 (en) * | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| CA3122223A1 (en) * | 2018-12-06 | 2020-06-11 | Intrabio Ltd | Deuterated analogs of acetyl-leucine |
| BR112021017203A2 (pt) | 2019-03-02 | 2021-12-14 | Intrabio Ltd | Leucina, acetil leucina e análogos relacionados para o tratamento de doenças |
| WO2021055443A1 (en) * | 2019-09-17 | 2021-03-25 | Hoffmann-La Roche Inc. | Improvements in personalized healthcare for patients with movement disorders |
| CA3164545A1 (en) * | 2020-01-13 | 2021-07-22 | Michael Strupp | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
-
2017
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/en active Pending
- 2017-08-11 RU RU2021128045A patent/RU2021128045A/ru unknown
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 US US16/324,353 patent/US20200179320A1/en active Pending
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 IL IL264641A patent/IL264641B1/en unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active IP Right Grant
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/en active Application Filing
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt active Search and Examination
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active IP Right Cessation
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/me unknown
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 CA CA3033564A patent/CA3033564A1/en active Pending
- 2017-08-11 MX MX2019001575A patent/MX2019001575A/es unknown
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/en active Active
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-06-12 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP2022003085A/ja active Pending
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121A1/en active Pending
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256383A1 (zh) | 治療劑 | |
| SI3600309T1 (sl) | Terapevtske kombinacije za zdravljenje bolezni jeter | |
| EP3227330C0 (en) | TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| IL265902A (en) | Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases | |
| SI3416631T1 (sl) | Terapevtska sredstva za nevrodegenerativne bolezni | |
| GB201509893D0 (en) | Therapeutic agents | |
| GB201517263D0 (en) | Therapeutic agents | |
| GB201603104D0 (en) | Therapeutic agents | |
| HK1258727A1 (zh) | 治療性化合物 | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| GB201509885D0 (en) | Therapeutic agents | |
| GB201509888D0 (en) | Therapeutic agents | |
| IL281869A (en) | Medical factor for neurodegenerative disease | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| GB201700553D0 (en) | Therapeutic agents | |
| GB201617339D0 (en) | Therapeutic compounds | |
| GB201616839D0 (en) | Therapeutic compounds | |
| GB201513299D0 (en) | Therapeutic agents | |
| GB201600376D0 (en) | Novel therapeutic agents | |
| SG11201705915VA (en) | Therapeutic agent for ischemic diseases | |
| GB201521767D0 (en) | Therapeutic agents | |
| IL263821A (en) | Medicinal compounds | |
| EP3560505A4 (en) | INNOVATIVE THERAPEUTICS FOR PRIONOID DISEASES | |
| GB201517264D0 (en) | Therapeutic agents | |
| GB201420348D0 (en) | Compounds for treating neurodegenerative diseases |